Professor Iain B Squire

Professor Iain SquireProfessor of Cardiovascular Medicine, University of Leicester & Honorary Consultant Physician, University Hospitals of Leicester

B.Sc. (Biochemistry and Pharmacology, Joint Honours)(1st Class) Strathclyde, 1982
M.B.,Ch.B. Glasgow, 1987
M.R.C.P. (UK) 1991
M.D. Glasgow, 1997
F.R.C.P. (London) 2002
F.E.S.C. 2014

Tel: +44 (0)116 204 4750 Email:

Address: Department of Cardiovascular Sciences, University of Leicester, Cardiovascular Research Centre, Glenfield General Hospital, Leicester, LE3 9QP

Personal details

B.Sc, M.B.,Ch.B, M.R.C.P., M.D., F.R.C.P., F.E.S.C.

I am Professor of Cardiovascular Medicine and University of Leicester & Honorary Consultant Physician, University Hospitals of Leicester.

Clinical trials

UK Principal Investigator and Steering Committee member for:

  • The ATLAS 2 ACS TIMI 51 Trial (Efficacy and Safety of Rivaroxaban in Subjects With a Recent Acute Coronary Syndrome) August 2009-2011; This international study enrolled over 13,000 patients
  • PARADIGM HF;  A multicentre, randomized, double-blind, active-controlled study to establish the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction.  November 2009- .  This international study is enrolling 8,000 patients. ONGOING
  • RELAX-AHF 2; A multicentre, randomized, double-blind, active-controlled study to establish the efficacy and safety of serelaxin in patients with acute heart failure
  • Protocol CRLX030A2209. Prospective, double-blind, multicenter study evaluating the safety of repeat doses of IV serelaxin in subjects with chronic heart failure. ONGOING
  • Clinical Trial Protocol CRLX030A2203. A multicenter, double blind, randomized, parallel group, placebo-controlled study to evaluate the effects of intravenous serelaxin infusion on micro- and macrovascular function in patients with coronary artery disease. ONGOING
  • Steering Group member: MAGGIC (Meta-analysis Global Group In Chronic Heart Failure) Study. An individual patient-level meta analysis comparing survival in patients with heart failure with low ejection fraction to those with preserved ejection fraction. Data from 46, 596 patients in 29 studies are being analysed, coordinated by Professor Rob Doughty, University of Auckland, New Zealand
  • A Double-blind, Randomized, Placebo-controlled, Multicenter, DoseEscalation Study to Select and Evaluate an Oral Modified Release Formulation of Omecamtiv Mecarbil in Subjects with Heart Failure and Left Ventricular Systolic Dysfunction; ONGOING
  • STOP CKD: Spironolactone to Prevent Cardiovascular Events in Early Stage Chronic Kidney Disease: A Pilot Trial. Data and Safety Monitoring Board Chair. August 2013-
  • Independent Data/Safety Monitoring Committee, Novartis CQAB 149B2348 trial

Other academic distinctions

  • Current Chair of British Society for Heart Failure (elected by Society Members); Previously Deputy Chair, Treasurer, and Councillor
  • Vice Chair, National Institute for Health and Care Excellence (NICE) Technology Appraisal Committee A
  • Myocardial Infarction National Audit Project (MINAP) Academic Group (MAG); invited membership June 2008-current
  • UK National Lead Investigator PARADIGM-HF trial; RELAX AHF2 trial
  • UK co-ordinator of a Europe-wide Cardiac Resynchronisation Registry, on behalf of the Heart Failure Association and Heart Rhythm Society of the European Society of Cardiology. July 2008-current
  • Editorial boards : Clinical Science Editorial Advisory Board August 2006-2012
  • British Journal of Clinical Pharmacology International Editorial Board, 2000-2004


Selected publications

  • Kristensen SL, Preiss D, Jhund PS, Squire I, Cardoso JS, Merkely B, Martinez F, Starling RC, Desai AS, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, McMurray JJ, Packer M. Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail. 2016 Jan;9(1). pii: e002560.
  • Jackson R, Brennan S, Fielding P, Sims MW, Challiss RAJ, Adlam D, Squire IB, Rainbow RD. Distinct and complementary roles for α and β isoenzymes of PKC in mediating vasoconstrictor responses to acutely elevated glucose. Brit.J.Pharmacol. 2016 Mar;173(5):870-87
  • Clark AL, Johnson M, Fairhurst C, Torgerson D, Cockayne S, Rodgers S, Griffin S, Allgar V, Jones L, Nabb S, Harvey I, Squire I, Murphy J, Greenstone M. Does home oxygen therapy (HOT) in addition to standard care reduce disease severity and improve symptoms in people with chronic heart failure? A randomised trial of home oxygen therapy for patients with chronic heart failure. Health Technol Assess. 2015 Sep;19(75):1-120.
  • Simpson J, Jhund PS, Cardoso JS, Martinez F, Mosterd A, Ramires F, Rizkala AR, Senni M, Squire I, Gong J, Lefkowitz MP, Shi VC, Desai AS, Rouleau JL, Swedberg K, Zile MR, McMurray JJV, Packer M, Solomon SD, on behalf of the PARADIGM-HF Investigators and Committees. Comparing LCZ696 With Enalapril According to Baseline Risk Using the MAGGIC and EMPHASIS-HF Risk Scores; An Analysis of Mortality and Morbidity in PARADIGM-HF. J Am Coll Cardiol 2015; 66:2059–71
  • Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015 Jun 18;372(25):2387-97.
  • Jackson CE, Castagno D, Maggioni AP, Kober L, Squire IB, Swedberg K, Andersson B, Richards AM, Bayes-Genis A, Tribouilloy C, Dobson J, Ariti C, Poppe KK, Earle N, Whalley G, Pocock SJ, Doughty RN, McMurray JJV. Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysis. European Heart Journal 2015 May 7;36(18):1106-14
  • Gholap NN, Khunti K, Davies MJ, Bodicoat DH, Squire IB. Survival in South Asian and White European patients after acute myocardial infarction. Heart. 2015 Apr;101(8):630-6.
  • McMurray J, Packer M, et al. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur. Heart J. 2014 Nov 21. pii: ehu455.
  • Packer M, McMurray JJ, Desai AS, et al. Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure. Circulation. 2014 Jan 6;131(1):54-61
  • Ng LL, Sandhu JK, Narayan H, Quinn PA, Squire IB, Davies JE, Struck J, Bergmann A, Maisel A, Jones DJL. Pro-Substance P for Evaluation of Risk in Acute Myocardial Infarction. JACC 2014; 64: 1698-1707
  • Devaux Y, Vausort M, McCann GP, Zangrando J, Kelly D, Razvi N, Zhang L, Ng LL, Wagner DR, Squire IB. MicroRNA-150: a novel marker of left ventricular remodeling after acute myocardial infarction. Circ Cardiovasc Genet. 2013 Jun;6(3):290-8
  • Martínez-Sellés M, Doughty RN, Poppe K, Whalley GA, Earle N, Tribouilloy C, McMurray JJ, Swedberg K, Køber L, Berry C, Squire I; Meta-Analysis Global Group In Chronic Heart Failure (MAGGIC). Gender and survival in patients with heart failure: interactions with diabetes and aetiology. Results from the MAGGIC individual patient meta-analysis. Eur J Heart Fail. 2012 May;14(5):473-9
  • Kelly D, Cockerill G, Ng LL, Thompson M, Khan S, Samani NJ, Squire IB. Plasma Tissue Inhibitor of Metalloproteinase-1 and Matrix Metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after Acute Myocardial Infarction. European Heart Journal 2008; doi:10.1093/eurheartj/ehn315.
  • Kelly D, Cockerill G, Ng LL, Thompson M, Khan S, Samani NJ, Squire IB. Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. European Heart Journal 2007; doi: 10.1093/eurheartj/ehm003
  • Blackledge HM, Newton J, Squire IB. Prognosis for South Asian and white patients newly hospitalised with heart failure in the UK: A historical cohort study. BMJ 2003; 327: 526-531
  • Squire IB, O’Kane KPJ, Anderson N, Reid JL. Bradykinin B2 receptor antagonism attenuates the blood pressure response to acute ACE inhibition in normal man. Hypertension; 2000; 36: 132-136
  • Squire IB, Lawley WJ, Fletcher S, Holme E, Hillis WS, Hewitt C, Woods KL. Humoral and cellular immune responses up to 7.5 years after administration of  streptokinase for acute myocardial infarction. Eur.Heart J, 1999; 20: 1245-1252

Book chapters

  • Squire IB. Aetiology and epidemiology of Chronic Heart Failure. In Oxford Cardiology Library: Chronic Heart Failure. MT Kearney (Editor). Oxford University Press 2008
  • Squire IB and Reid JL.  Implications for the pathophysiology of hypertension and heart failure derived from clinical experience with drugs modifying the renin angiotensin system. IN: Enzymes and receptors of the Renin Angiotensin System: Celebrating a century of discovery.  pp 175-186. A.Husain & R.Graham, Eds. Harwood Academic Publishers, Amsterdam, 2000
  • Squire IB and Barnett DB. Inotropic agents: dead and buried ? In: Heart Failure in Clinical Practice 257-270;  JJV McMurray & JGF Cleland, Eds. Martin Dunitz London 1996
  • Squire IB, Reid JL. Interactions Between the Renin-Angiotensin System and the Autonomic Nervous System.    IN: The Renin Angiotensin System: 37.1-37.16. J.I.S. Robertson, M.G.Nicholls, Editors. Gower Medical Publishing, London 1993

Full lists of publications


Before 2006


  • Natriuretic peptides and other peptide markers in heart failure

  • Epidemiology of heart failure

  • Clinical trials in heart failure

  • Epidemiology and management of acute coronary artery disease

  • Advanced nursing issues in the management of heart failure

Share this page: